UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027441
Receipt number R000031431
Scientific Title The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)
Date of disclosure of the study information 2017/05/23
Last modified on 2017/05/22 16:33:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

Acronym

Hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

Scientific Title

The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

Scientific Title:Acronym

Hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

Region

Japan


Condition

Condition

Resectable pancreatic cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

In pancreatic cancer, we examine the safety and anti-tumor effect of 3-oxygelmillpropionic acid polymer (a trade name: Seroshion) .

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

safety

Key secondary outcomes

efficacy


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The dose of Seroshion is 1 capsule (10mg) /time after each meal (3 times/day,30mg/day). The administration period is six months.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) The case who was diagnosed histologically pancreatic cancer (2)The case who underwent R0 resection for pancreatic cancer.(3)The age is over 20 years old.(4)PS (ECOG) is 0 or 1. (5)Within 14 days before,major organ function is held by clinical examination.1)WBC is above 3,000 / mm3 and below 12,000/mm3. 2)Plt is above 100,000/mm3, 3)Hb is above 8.0g / dL, 4)AST (GOT) is below 100IU / L, and ALT (GPT)is below 100IU/L. 5)T-bil is below 2.0mg/dL. 6)Cr is below 1.2mg/dL 7)Ccr is above 50mL/min. (6)The patients can eat orally. (7)The patients who can start treatment within 4 to 12 weeks after surgery. (8)The patients who obtained the written consent before performing the various procedures for the test. Patients who can understand and are willing to sign the contents of the consent document.

Key exclusion criteria

(1)Patients who could not resected curatively.(2)Patients with active double cancer. (3)Patients with serious drug hypersensitivity or with a history of drug allergy.(4)Patients with serious complications.(5)Patients with jaundice,cirrhosis or with suspected cirrhosis of the liver.(6)There is a history of chronic hepatitis B, and in the present study drug has already been ingested.(7)Patients with active infection.(8)Women who have a possibility of or in the pregnancy,who hope to become pregnant,or who are breast-feeding. Men who wish to become pregnant partner.(9)Patients with severe mental disorder.(10)Other patients whom the physician decided to be unsuitable for safely carrying out the present study.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hidetoshi Eguchi

Organization

Osaka University,Graduate School of Medicine

Division name

Gastroenterological Surgery

Zip code


Address

2-2,Yamadaoka,Suita City, Osaka

TEL

0668793251

Email

heguchi@gesurg.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hidetoshi Eguchi

Organization

Osaka University,Graduate School of Medicine

Division name

Gastroenterological Surgery

Zip code


Address

2-2,Yamadaoka,Suita City, Osaka

TEL

0668793251

Homepage URL


Email

heguchi@gesurg.med.osaka-u.ac.jp


Sponsor or person

Institute

Osaka University

Institute

Department

Personal name



Funding Source

Organization

National Institute of Public Health

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2015 Year 10 Month 13 Day

Date of IRB


Anticipated trial start date

2015 Year 10 Month 14 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 05 Month 22 Day

Last modified on

2017 Year 05 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031431


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name